Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. - Wikidata - wikimedia - TriplyDB

Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.

Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.

http://www.wikidata.org/entity/Q37457945

about

ITIH5 mediates epigenetic reprogramming of breast cancer cells.Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia Unlocking the epigenetic code of T cell exhaustion.Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.

P2860

Q37661492-61F8D802-60A6-4C5C-9B21-FD3B7F73E24F Q42371573-E029C70D-E553-4CB5-9B59-F41DBA9C5600 Q47106834-FDA06162-40A8-4F62-A619-916A5A59FDED Q47151143-D05F58AA-E1EC-4842-8E8F-978179A0A112

P2860

Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.

http://www.wikidata.org/entity/Q37457945

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@en

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@nl

type

label

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@en

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@nl

prefLabel

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@en

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@nl

P1433

Q37457945-FFED2679-9B91-46EF-AB07-B6E8DB6E7FD8

P1476

Q37457945-F9C94AA4-31AC-4078-8543-1166CB4D7948

P2093

Q37457945-179F05C9-F1FE-4AB8-921B-4C5AB57C779A

Q37457945-2531260E-C629-4D64-8CC9-72B56A266DD0

Q37457945-2B4AE71D-F543-4F24-AF23-1E6AD3E32CFF

Q37457945-2EE6A117-DFAE-453C-8D65-34B018DDD152

Q37457945-3BC34790-EC50-4A16-BEA0-4F529BA744CE

Q37457945-5552352D-C891-4B87-A351-C4D28D494821

Q37457945-5A3A20F0-3667-4DCF-AA48-32FCD4590926

Q37457945-660F077A-3E17-480D-BFD2-D9BF0B6567FE

Q37457945-684EF027-B008-4225-B555-784593A08FC9

Q37457945-73550669-4F25-43FF-B187-EC151152A6F9

P2860

Q37457945-0F1F3879-2ABB-4D28-A3AB-C12A74FC9C0F

Q37457945-342960FA-BF37-46F7-B55B-051BABF044B9

Q37457945-3DE3CD46-A92D-4C95-AA77-1289D80963A7

Q37457945-45386AC2-BACB-40A9-8EAF-C8F867824A3C

Q37457945-46AD44EC-B6E3-4A84-A24A-CF67521D9A91

Q37457945-46DB7096-8016-4EF2-AB4E-ADFBF4422574

Q37457945-598E8BEB-E960-43FE-BD49-40E0E56F0883

Q37457945-5A095D7A-AB5C-4280-A406-D922D727701F

Q37457945-5C352061-6965-4B99-9C79-3002B8952902

Q37457945-60D31D7D-2FE0-48D0-A538-4049DA93815E

P304

Q37457945-6DFE1975-ABFF-4067-AA1B-68DEECE702CB

P31

Q37457945-628693A1-C1DA-4CB1-8DCD-0788FCEC9ED6

P356

Q37457945-B72F4AD0-0EAC-4CA8-BDA1-340B382F77FA

P407

Q37457945-376CC216-483A-486E-B395-0716063873C0

P433

Q37457945-09BBCDC4-4F9A-4B09-AD73-141BFA5EF967

P478

Q37457945-79DBD364-8803-4987-8951-F5253F6425B2

P577

Q37457945-E6F0DCCD-6A68-4C70-BA2D-7873B750D817

P698

Q37457945-0AE4336C-C14B-48B7-91F1-DAE17138377A

P921

Q37457945-E2493D41-363F-4011-ABBF-BF2F91F8ECB5

Q37457945-F6FE5029-3743-42AF-82E0-1B7360BBCADD

P932

Q37457945-EA5F1D58-41BD-4234-A075-6B0419946232

P356

ONCOTARGET.9941

P1433

P1476

Phenotypic alteration of CD8+ ...... with epigenetic reprogramming.

@en

P2093

Austin Y Shull

http://www.w3.org/2001/XMLSchema#string

Eun-Joon Lee

http://www.w3.org/2001/XMLSchema#string

Farrukh Awan

http://www.w3.org/2001/XMLSchema#string

Hong-Bo Xin

http://www.w3.org/2001/XMLSchema#string

Huidong Shi

http://www.w3.org/2001/XMLSchema#string

Jeong-Hyeon Choi

http://www.w3.org/2001/XMLSchema#string

Jianyong Li

http://www.w3.org/2001/XMLSchema#string

Jiazhu Wu

http://www.w3.org/2001/XMLSchema#string

Jinhua Liang

http://www.w3.org/2001/XMLSchema#string

Lei Fan

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

PD-1 and its ligands in tolerance and immunity

Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)

The CC chemokine CCL20 and its receptor CCR6.

Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

How I treat CLL up front.

Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.

2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells.

P304

40558-40570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9941

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27302925

http://www.w3.org/2001/XMLSchema#string

P921

P932

5130028

http://www.w3.org/2001/XMLSchema#string